Nanomedicine based nanoparticles for neurological disorders

Current Medicinal Chemistry

Volumn 21, Issue 36, 2014, Pages 4154-4168

  Sriramoju, Bhasker ^a   Kanwar, Rupinder K ^a   Kanwar, Jagat R ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

Blood brain barrier; Nanomedicine; Neurological disorders; Polymeric nanoparticles; Targeted therapeutics

Indexed keywords

ABS 75; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CARBON NANOFIBER; CARBON NANOTUBE; DENDRIMER; DEXTRAN MAGNETITE; DOXORUBICIN; FULLERENE DERIVATIVE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR ANTAGONIST; GOLD NANOPARTICLE; LIPOSOME; METAL NANOPARTICLE; MOLECULAR SCAFFOLD; MONOCLONAL ANTIBODY; MONOCRYSTALLINE IRON OXIDE NANOPARTICLE; NANOCAPSULE; NANOLIPOSOME; NANOPARTICLE; NANOSPHERE; NERVE GROWTH FACTOR; PACLITAXEL; PENICILLAMINE; POLYAMIDOAMINE; POLYMER; SILVER NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TRANSACTIVATOR PROTEIN; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG CARRIER; NEUROPROTECTIVE AGENT;

ADSORPTION; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CEREBROVASCULAR ACCIDENT; COVALENT BOND; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSPORT; GEL; GLIOMA; HUMAN; MICELLE; MULTIPLE SCLEROSIS; NANOFORMULATION; NANOGEL; NANOMEDICINE; NANOMICELLE; NANOSUSPENSION; NERVE REGENERATION; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; SUSPENSION; TUMOR LOCALIZATION; CHEMISTRY; METABOLISM; NERVOUS SYSTEM DISEASES;

BLOOD-BRAIN BARRIER; DRUG CARRIERS; HUMANS; NANOMEDICINE; NANOPARTICLES; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; POLYMERS;

EID: 84928654680     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140716095644     Document Type: Article

References (140)

1. Zlokovic, B. V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron, 2008, 57(2), 178-201.
2. B, J. Cost of disorders of the brain in Europe. Eur. J Neurol., 2005, 12, 8-9.
3. Kanwar, J. R.; Sun, X.; Punj, V.; Sriramoju, B.; Mohan, R. R.; Zhou, S. F.; Chauhan, A.; Kanwar, R. K. Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal. Nanomedicine, 2012, 8(4), 399-414.
4. Singh, N.; Pillay, V.; Choonara, Y. E. Advances in the treatment of Parkinson's disease. Prog. Neurobiol., 2007, 81(1), 29-44.
5. Westphal, M.; Lamszus, K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat. Rev. Neurosci., 2011, 12(9), 495-508.
6. Xu, D.; Bureau, Y.; McIntyre, D. C.; Nicholson, D. W.; Liston, P.; Zhu, Y.; Fong, W. G.; Crocker, S. J.; Korneluk, R. G.; Robertson, G. S. Attenuation of ischemia-induced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus. J. Neurosci., 1999, 19(12), 5026-5033.
7. Louis, D. N.; Ohgaki, H.; Wiestler, O. D.; Cavenee, W. K.; Burger, P. C.; Jouvet, A.; Scheithauer, B. W.; Kleihues, P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol., 2007, 114(2), 97-109.
8. Clarke, J.; Butowski, N.; Chang, S. Recent advances in therapy for glioblastoma. Arch. Neurol., 2010, 67(3), 279-283.
9. Compston, A.; Coles, A. Multiple sclerosis. Lancet, 2002, 359(9313), 1221-1231.
10. Nowacek, A.; Kosloski, L. M.; Gendelman, H. E. Neurodegenerative disorders and nanoformulated drug development. Nanomedicine (Lond), 2009, 4(5), 541-555.
11. Pardridge, W. M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx, 2005, 2(1), 3-14.
12. Kreuter, J.; Shamenkov, D.; Petrov, V.; Ramge, P.; Cychutek, K.; Koch-Brandt, C.; Alyautdin, R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target., 2002, 10(4), 317-325.
13. Kabanov, A. V.; Gendelman, H. E. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog. Polym. Sci., 2007, 32(8-9), 1054-1082.
14. Brightman, M. W.; Kaya, M. Permeable endothelium and the interstitial space of brain. Cell. Mol. Neurobiol., 2000, 20(2), 111-130.
15. Siegal, T.; Rubinstein, R.; Bokstein, F.; Schwartz, A.; Lossos, A.; Shalom, E.; Chisin, R.; Gomori, J. M. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. J. Neurosurg., 2000, 92(4), 599-605.
16. Kaya, M.; Chang, L.; Truong, A.; Brightman, M. W. Chemical induction of fenestrae in vessels of the blood-brain barrier. Exp. Neurol., 1996, 142(1), 6-13.
17. Silva, G. A. Neuroscience nanotechnology: progress, opportunities and challenges. Nat. Rev. Neurosci., 2006, 7(1), 65-74.
18. Kanwar, J. R.; Sriramoju, B.; Kanwar, R. K. Neurological disorders and therapeutics targeted to surmount the blood-brain barrier. Int. J. Nanomedicine, 2012, 7, 3259-3278.
19. Behan, N.; Birkinshaw, C.; Clarke, N. Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerisation and particle formation. Biomaterials, 2001, 22(11), 1335-1344.
20. Thorne, R. G.; Nicholson, C. In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. Proc. Natl. Acad. Sci. USA, 2006, 103(14), 5567-5572.
21. Modi, G.; Pillay, V.; Choonara, Y. E.; Ndesendo, V. M.; Du Toit, L. C.; Naidoo, D. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog. Neurobiol., 2009, 88(4), 272-285.
22. Alyaudtin, R. N.; Reichel, A.; Lobenberg, R.; Ramge, P.; Kreuter, J.; Begley, D. J. Interaction of poly (butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J. Drug Target., 2001, 9(3), 209-221.
23. Calvo, P.; Gouritin, B.; Chacun, H.; Desmaele, D.; D'Angelo, J.; Noel, J. P.; Georgin, D.; Fattal, E.; Andreux, J. P.; Couvreur, P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res., 2001, 18(8), 1157-1166.
24. Modi, G.; Pillay, V.; Choonara, Y. E. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann. N. Y. Acad. Sci., 2010, 1184, 154-172.
25. Bernardi, A.; Frozza, R. L.; Horn, A. P.; Campos, M. M.; Calixto, J. B.; Salbego, C.; Pohlmann, A. R.; Guterres, S. S.; Battastini, A. M. Protective effects of indomethacin-loaded nanocapsules against oxygen-glucose deprivation in organotypic hippocampal slice cultures: involvement of neuroinflammation. Neurochem. Int., 2010, 57(6), 629-636.
26. Harada-Shiba, M.; Yamauchi, K.; Harada, A.; Takamisawa, I.; Shimokado, K.; Kataoka, K. Polyion complex micelles as vectors in gene therapy-pharmacokinetics and in vivo gene transfer. Gene Ther., 2002, 9(6), 407-414.
27. Nguyen, H. K.; Lemieux, P.; Vinogradov, S. V.; Gebhart, C. L.; Guerin, N.; Paradis, G.; Bronich, T. K.; Alakhov, V. Y.; Kabanov, A. V. Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents. Gene Ther., 2000, 7(2), 126-138.
28. Pai, A. S.; Rubinstein, I.; Onyuksel, H. PEGylated phospholipid nanomicelles interact with beta-amyloid ((1-42)) and mitigate its beta-sheet formation, aggregation and neurotoxicity in vitro. Peptides, 2006, 27(11), 2858-2866.
29. Torchilin, V. P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res., 2007, 24(1), 1-16.
30. Kumar RM, S. M. Polymeric nanoparticles for drug and gene delivery. American Scientific Publishers, 2003.
31. Patravale, V. B.; Date, A. A.; Kulkarni, R. M. Nanosuspensions: a promising drug delivery strategy. J. Pharm. Pharmacol., 2004, 56(7), 827-840.
32. Vinogradov, S. V.; Zeman, A. D.; Batrakova, E. V.; Kabanov, A. V. Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs. J. Control. Release, 2005, 107(1), 143-157.
33. Vinogradov, S. V.; Batrakova, E. V.; Kabanov, A. V. Nanogels for oligonucleotide delivery to the brain. Bioconjug. Chem., 2004, 15(1), 50-60.
34. Voinea, M.; Simionescu, M. Designing of 'intelligent' liposomes for efficient delivery of drugs. J. Cell. Mol. Med., 2002, 6(4), 465-474.
35. Mourtas, S.; Canovi, M.; Zona, C.; Aurilia, D.; Niarakis, A.; La Ferla, B.; Salmona, M.; Nicotra, F.; Gobbi, M.; Antimisiaris, S. G. Curcumin-decorated nanoliposomes with very high affinity for amyloid-beta1-42 peptide. Biomaterials, 2011, 32(6), 1635-1645.
36. Couvreur P, A. J. In Topics in Pharmaceutical Sciences. Breimer DD, S. P. Ed.; Elsevier Sciences Publishers Amsterdam, 1983. pp 305-316.
37. Manil, L.; Roblot-Treupel, L.; Couvreur, P. Isobutyl cyanoacrylate nanoparticles as a solid phase for an efficient immunoradiometric assay. Biomaterials, 1986, 7(3), 212-216.
38. Illum, L.; Jones, P. D. E.; Kreuter, J.; Baldwin, R. W.; Davis, S. S. Adsorption of monoclonal antibodies to polyhexylcyanoacrylate nanoparticles and subsequent immunospecific binding to tumour cells in vitro. Int. J. Pharm., 1983, 17(1), 65-76.
39. Blackwell, J. E.; Dagia, N. M.; Dickerson, J. B.; Berg, E. L.; Goetz, D. J. Ligand coated nanosphere adhesion to E- and P-selectin under static and flow conditions. Ann. Biomed. Eng., 2001, 29(6), 523-533.
40. Akasaka, Y.; Ueda, H.; Takayama, K.; Machida, Y.; Nagai, T. Preparation and evaluation of bovine serum albumin nanospheres coated with monoclonal antibodies. Drug Des. Deliv., 1988, 3(1), 85-97.
41. Rolland, A.; Bourel, D.; Genetet, B.; Le Verge, R. Monoclonal antibodies covalently coupled to polymethacrylic nanoparticles: in vitro specific targeting to human T lymphocytes. Int. J. Pharm., 1987, 39(1-2), 173-180.
42. Li, Y.; Ogris, M.; Wagner, E.; Pelisek, J.; Rüffer, M. Nanoparticles bearing polyethyleneglycol-coupled transferrin as gene carriers: preparation and in vitro evaluation. Int. J. Pharm., 2003, 259(1-2), 93-101.
43. Irache, J. M.; Durrer, C.; Duchene, D.; Ponchel, G. Preparation and characterization of lectin-latex conjugates for specific bioadhesion. Biomaterials, 1994, 15(11), 899-904.
44. Sperling, R. A.; Parak, W. J. Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles. Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences, 2010, 368(1915), 1333-1383.
45. Kateb, B.; Yamamoto, V.; Alizadeh, D.; Zhang, L.; Manohara, H. M.; Bronikowski, M. J.; Badie, B. Multi-walled carbon nanotube (MWCNT) synthesis, preparation, labeling, and functionalization. Methods Mol. Biol., 2010, 651, 307-317.
46. Matsumoto, K.; Sato, C.; Naka, Y.; Whitby, R.; Shimizu, N. Stimulation of neuronal neurite outgrowth using functionalized carbon nanotubes. Nanotechnology, 2010, 21(11), 115101.
47. Du Toit, L. C.; Pillay, V.; Choonara, Y. E.; Pillay, S.; Harilall, S. L. Patenting of nanopharmaceuticals in drug delivery: no small issue. Recent Pat. Drug Deliv. Formul., 2007, 1(2), 131-142.
48. Zhang, L.; Gu, F. X.; Chan, J. M.; Wang, A. Z.; Langer, R. S.; Farokhzad, O. C. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther., 2008, 83(5), 761-769.
49. Albertazzi, L.; Gherardini, L.; Brondi, M.; Sulis Sato, S.; Bifone, A.; Pizzorusso, T.; Ratto, G. M.; Bardi, G. In vivo distribution and toxicity of PAMAM dendrimers in the central nervous system depend on their surface chemistry. Mol. Pharm., 2013, 10(1), 249-260.
50. Mody, V. V.; Siwale, R.; Singh, A.; Mody, H. R. Introduction to metallic nanoparticles. J. Pharm. Bioallied Sci., 2010, 2(4), 282-289.
51. Babes, L.; Denizot, B.; Tanguy, G.; Le Jeune, J. J.; Jallet, P. Synthesis of Iron Oxide Nanoparticles Used as MRI Contrast Agents: A Parametric Study. J. Colloid Interface Sci., 1999, 212(2), 474-482.
52. Shen, T.; Weissleder, R.; Papisov, M.; Bogdanov, A. Jr.; Brady, T. J. Monocrystalline iron oxide nanocompounds (MION): physicochemical properties. Magn. Reson. Med., 1993, 29(5), 599-604.
53. Giljohann, D. A.; Seferos, D. S.; Daniel, W. L.; Massich, M. D.; Patel, P. C.; Mirkin, C. A. Gold nanoparticles for biology and medicine. Angewandte Chemie, 2010, 49(19), 3280-3294.
54. G. F. Controlled nulceation for regulation of particle size in monodisperse gold suspensions. Na Phys Sci. 1973, 241, 20-22.
55. Stepanov AL, P. V. Hole DE, Formation of Metallic Nanoparticles in Silicate Glass through Ion Implantation. Glass Phy. Chem., 2002, 28, 90-95.
56. Misgeld, T.; Kerschensteiner, M. In vivo imaging of the diseased nervous system. Nat. Rev. Neurosci., 2006, 7(6), 449-463.
57. Llinás, R.; Walton, K.; Nakao, M.; Hunter, I.; Anquetil, P. Neurovascular central nervous recording/stimulating system: Using nanotechnology probes. J. Nanopart. Res., 2005, 7(2-3), 111-127.
58. Weinstein, J. S.; Varallyay, C. G.; Dosa, E.; Gahramanov, S.; Hamilton, B.; Rooney, W. D.; Muldoon, L. L.; Neuwelt, E. A. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J. Cereb. Blood Flow Metab., 2010, 30(1), 15-35.
59. Neuwelt, E. A.; Varallyay, P.; Bago, A. G.; Muldoon, L. L.; Nesbit, G.; Nixon, R. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours. Neuropathol. Appl. Neurobiol., 2004, 30(5), 456-471.
60. Petry, K. G.; Boiziau, C.; Dousset, V.; Brochet, B. Magnetic resonance imaging of human brain macrophage infiltration. Neurotherapeutics, 2007, 4(3), 434-442.
61. Mykhaylyk, O.; Cherchenko, A.; Ilkin, A.; Dudchenko, N.; Ruditsa, V.; Novoseletz, M.; Zozulya, Y. Glial brain tumor targeting of magnetite nanoparticles in rats. J. Magn. Magn. Mater., 2001, 225(1-2), 241-247.
62. Santra, S.; Yang, H.; Stanley, J. T.; Holloway, P. H.; Moudgil, B. M.; Walter, G.; Mericle, R. A. Rapid and effective labeling of brain tissue using TAT-conjugated CdS: Mn/ZnS quantum dots. Chem. Commun. (Camb.), 2005(25), 3144-3146.
63. Yan, H.; Wang, J.; Yi, P.; Lei, H.; Zhan, C.; Xie, C.; Feng, L.; Qian, J.; Zhu, J.; Lu, W.; Li, C. Imaging brain tumor by dendrimerbased optical/paramagnetic nanoprobe across the blood-brain barrier. Chem. Commun. (Camb.), 2011, 47(28), 8130-8132.
64. Keefer, E. W.; Botterman, B. R.; Romero, M. I.; Rossi, A. F.; Gross, G. W. Carbon nanotube coating improves neuronal recordings. Nat. Nanotechnol., 2008, 3(7), 434-439.
65. Steiniger, S. C.; Kreuter, J.; Khalansky, A. S.; Skidan, I. N.; Bobruskin, A. I.; Smirnova, Z. S.; Severin, S. E.; Uhl, R.; Kock, M.; Geiger, K. D.; Gelperina, S. E. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer, 2004, 109(5), 759-767.
66. Jiang, X.; Xin, H.; Sha, X.; Gu, J.; Jiang, Y.; Law, K.; Chen, Y.; Chen, L.; Wang, X.; Fang, X. PEGylated poly (trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation. Int. J. Pharm., 2011, 420(2), 385-394.
67. Zhao, M.; Liang, C.; Li, A.; Chang, J.; Wang, H.; Yan, R.; Zhang, J.; Tai, J. Magnetic paclitaxel nanoparticles inhibit glioma growth and improve the survival of rats bearing glioma xenografts. Anticancer Res., 2010, 30(6), 2217-2223.
68. Van Landeghem, F. K.; Maier-Hauff, K.; Jordan, A.; Hoffmann, K. T.; Gneveckow, U.; Scholz, R.; Thiesen, B.; Bruck, W.; Von Deimling, A. Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. Biomaterials, 2009, 30(1), 52-57.
69. Agemy, L.; Friedmann-Morvinski, D.; Kotamraju, V. R.; Roth, L.; Sugahara, K. N.; Girard, O. M.; Mattrey, R. F.; Verma, I. M.; Ruoslahti, E. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc. Natl. Acad. Sci., 2011.
70. Wu, G.; Barth, R. F.; Yang, W.; Kawabata, S.; Zhang, L.; Green-Church, K. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMCC225) dendrimer bioconjugates. Mol. Cancer Ther., 2006, 5(1), 52-59.
71. Doi, A.; Kawabata, S.; Iida, K.; Yokoyama, K.; Kajimoto, Y.; Kuroiwa, T.; Shirakawa, T.; Kirihata, M.; Kasaoka, S.; Maruyama, K.; Kumada, H.; Sakurai, Y.; Masunaga, S.; Ono, K.; Miyatake, S. Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. J. Neurooncol., 2008, 87(3), 287-294.
72. Feng, B.; Tomizawa, K.; Michiue, H.; Miyatake, S.; Han, X. J.; Fujimura, A.; Seno, M.; Kirihata, M.; Matsui, H. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials, 2009, 30(9), 1746-1755.
73. Van Handel, M.; Alizadeh, D.; Zhang, L.; Kateb, B.; Bronikowski, M.; Manohara, H.; Badie, B. Selective uptake of multi-walled carbon nanotubes by tumor macrophages in a murine glioma model. J. Neuroimmunol., 2009, 208(1-2), 3-9.
74. Ren, J.; Shen, S.; Wang, D.; Xi, Z.; Guo, L.; Pang, Z.; Qian, Y.; Sun, X.; Jiang, X. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials, 2012, 33(11), 3324-3333.
75. Cui, Z.; Lockman, P. R.; Atwood, C. S.; Hsu, C. H.; Gupte, A.; Allen, D. D.; Mumper, R. J. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur. J. Pharm. Biopharm., 2005, 59(2), 263-272.
76. Liu, G.; Men, P.; Harris, P. L.; Rolston, R. K.; Perry, G.; Smith, M. A. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci. Lett., 2006, 406(3), 189-193.
77. Liu, G.; Men, P.; Kudo, W.; Perry, G.; Smith, M. A. Nanoparticlechelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci. Lett., 2009, 455(3), 187-190.
78. Reddy, M. K.; Wu, L.; Kou, W.; Ghorpade, A.; Labhasetwar, V. Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. Appl. Biochem. Biotechnol., 2008, 151(2-3), 565-577.
79. Schubert, D.; Dargusch, R.; Raitano, J.; Chan, S. W. Cerium and yttrium oxide nanoparticles are neuroprotective. Biochem. Biophys. Res. Commun., 2006, 342(1), 86-91.
80. Cho, Y.; Shi, R.; Ben Borgens, R. Chitosan nanoparticle-based neuronal membrane sealing and neuroprotection following acrolein-induced cell injury. J. Biol. Eng., 2010, 4(1), 2.
81. Podolski, I. Y.; Podlubnaya, Z. A.; Kosenko, E. A.; Mugantseva, E. A.; Makarova, E. G.; Marsagishvili, L. G.; Shpagina, M. D.; Kaminsky, Y. G.; Andrievsky, G. V.; Klochkov, V. K. Effects of hydrated forms of C60 fullerene on amyloid 1-peptide fibrillization in vitro and performance of the cognitive task. J. Nanosci. Nanotechnol., 2007, 7(4-5), 1479-1485.
82. Batrakova, E. V.; Li, S.; Reynolds, A. D.; Mosley, R. L.; Bronich, T. K.; Kabanov, A. V.; Gendelman, H. E. A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug. Chem., 2007, 18(5), 1498-1506.
83. Gonzalez-Barrios, J. A.; Lindahl, M.; Bannon, M. J.; Anaya-Martinez, V.; Flores, G.; Navarro-Quiroga, I.; Trudeau, L. E.; Aceves, J.; Martinez-Arguelles, D. B.; Garcia-Villegas, R.; Jimenez, I.; Segovia, J.; Martinez-Fong, D. Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats. Mol. Ther., 2006, 14(6), 857-865.
84. Crotty, S.; Fitzgerald, P.; Tuohy, E.; Harris, D. M.; Fisher, A.; Mandel, A.; Bolton, A. E.; Sullivan, A. M.; Nolan, Y. Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease. Eur. J. Neurosci., 2008, 27(2), 294-300.
85. Kurakhmaeva, K. B.; Djindjikhashvili, I. A.; Petrov, V. E.; Balabanyan, V. U.; Voronina, T. A.; Trofimov, S. S.; Kreuter, J.; Gelperina, S.; Begley, D.; Alyautdin, R. N. Brain targeting of nerve growth factor using poly (butyl cyanoacrylate) nanoparticles. J. Drug Target., 2009, 17(8), 564-574.
86. Wen, Z.; Yan, Z.; Hu, K.; Pang, Z.; Cheng, X.; Guo, L.; Zhang, Q.; Jiang, X.; Fang, L.; Lai, R. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration. J. Control. Release, 2011, 151(2), 131-138.
87. Karatas, H.; Aktas, Y.; Gursoy-Ozdemir, Y.; Bodur, E.; Yemisci, M.; Caban, S.; Vural, A.; Pinarbasli, O.; Capan, Y.; Fernandez-Megia, E.; Novoa-Carballal, R.; Riguera, R.; Andrieux, K.; Couvreur, P.; Dalkara, T. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J. Neurosci., 2009, 29(44), 13761-13769.
88. Kim, I. D.; Lim, C. M.; Kim, J. B.; Nam, H. Y.; Nam, K.; Kim, S. W.; Park, J. S.; Lee, J. K. Neuroprotection by biodegradable PAMAM ester (e-PAM-R)-mediated HMGB1 siRNA delivery in primary cortical cultures and in the postischemic brain. J. Control. Release, 2010, 142(3), 422-430.
89. Kawaguchi, A. T.; Kurita, D.; Furuya, H.; Yamano, M.; Ogata, Y.; Haida, M. Liposome-encapsulated hemoglobin alleviates brain edema after permanent occlusion of the middle cerebral artery in rats. Artif. Organs, 2009, 33(2), 153-158.
90. Lee, H. J.; Park, J.; Yoon, O. J.; Kim, H. W.; Lee Do, Y.; Kim Do, H.; Lee, W. B.; Lee, N. E.; Bonventre, J. V.; Kim, S. S. Amine-modified single-walled carbon nanotubes protect neurons from injury in a rat stroke model. Nat. Nanotechnol., 2011, 6(2), 121-125.
91. Basso, A. S.; Frenkel, D.; Quintana, F. J.; Costa-Pinto, F. A.; Petrovic-Stojkovic, S.; Puckett, L.; Monsonego, A.; Bar-Shir, A.; Engel, Y.; Gozin, M.; Weiner, H. L. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J. Clin. Invest., 2008, 118(4), 1532-1543.
92. Holmes, T. C.; De Lacalle, S.; Su, X.; Liu, G.; Rich, A.; Zhang, S. Extensive neurite outgrowth and active synapse formation on self-assembling peptide scaffolds. Proc. Natl. Acad. Sci. U S A, 2000, 97(12), 6728-6733.
93. Tysseling-Mattiace, V. M.; Sahni, V.; Niece, K. L.; Birch, D.; Czeisler, C.; Fehlings, M. G.; Stupp, S. I.; Kessler, J. A. Self-assembling nanofibers inhibit glial scar formation and promote axon elongation after spinal cord injury. J. Neurosci., 2008, 28(14), 3814-3823.
94. Muruganandam, A.; Tanha, J.; Narang, S.; Stanimirovic, D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB, 2002, 16(2), 240-242.
95. Zhang, Y.; Pardridge, W. M. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J. Pharm. Exp. Ther., 2005, 313(3), 1075-1081.
96. Coloma, M. J.; Lee, H. J.; Kurihara, A.; Landaw, E. M.; Boado, R. J.; Morrison, S. L.; Pardridge, W. M. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res., 2000, 17(3), 266-274.
97. Demeule, M.; Currie, J. C.; Bertrand, Y.; Che, C.; Nguyen, T.; Regina, A.; Gabathuler, R.; Castaigne, J. P.; Beliveau, R. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J. Neurochem., 2008, 106(4), 1534-1544.
98. Gaillard, P. J.; Visser, C. C.; De Boer, A. G. Targeted delivery across the blood-brain barrier. Exp. Opin. Drug Deliv., 2005, 2(2), 299-309.
99. Phillips, M. A.; Gran, M. L.; Peppas, N. A. Targeted Nanodelivery of Drugs and Diagnostics. Nano Today, 2010, 5(2), 143-159.
100. P. M. F. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates. November 10, 1998.
101. Wu, D.; Yang, J.; Pardridge, W. M. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Invest., 1997, 100(7), 1804-1812.
102. Starr CM, Z. T. Gabathuler R Delivery of therapeutic compounds to the brain and other tissues. January 13, 2005.
103. Liu, Z.; Gao, X.; Kang, T.; Jiang, M.; Miao, D.; Gu, G.; Hu, Q.; Song, Q.; Yao, L.; Tu, Y.; Chen, H.; Jiang, X.; Chen, J. B6 Peptide-Modified PEG-PLA Nanoparticles for Enhanced Brain Delivery of Neuroprotective Peptide. Bioconjug. Chem., 2013, 24(6), 997-1007.
104. Gaillard PJ, V. C. Appeldoorn CCM, Rip J, Enhanced brain drug delivery: safely crossing the blood-brain barrier. Drug Discov. Today Technol., 2012, (9:e), 155-160.
105. Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev., 2001, 47(1), 65-81.
106. Wang, C. X.; Huang, L. S.; Hou, L. B.; Jiang, L.; Yan, Z. T.; Wang, Y. L.; Chen, Z. L. Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model. Brain Res., 2009, 1261, 91-99.
107. Kulkarni, S. A.; Feng, S. S. Effects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood-brain barrier. Nanomedicine (Lond), 2011, 6(2), 377-394.
108. Gan, C. W.; Feng, S. S. Transferrin-conjugated nanoparticles of poly (lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials, 2010, 31(30), 7748-7757.
109. Carroll, R. T.; Bhatia, D.; Geldenhuys, W.; Bhatia, R.; Miladore, N.; Bishayee, A.; Sutariya, V. Brain-targeted delivery of Tempolloaded nanoparticles for neurological disorders. J. Drug Target., 2010, 18(9), 665-674.
110. Huang, R.; Ke, W.; Han, L.; Liu, Y.; Shao, K.; Jiang, C.; Pei, Y. Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo. Brain Res. Bull., 2010, 81(6), 600-604.
111. Huang, S.; Li, J.; Han, L.; Liu, S.; Ma, H.; Huang, R.; Jiang, C. Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma. Biomaterials, 2011, 32(28), 6832-6838.
112. Li, J.; Feng, L.; Fan, L.; Zha, Y.; Guo, L.; Zhang, Q.; Chen, J.; Pang, Z.; Wang, Y.; Jiang, X.; Yang, V. C.; Wen, L. Targeting the brain with PEG-PLGA nanoparticles modified with phagedisplayed peptides. Biomaterials, 2011, 32(21), 4943-4950.
113. Huang, R.; Ke, W.; Han, L.; Li, J.; Liu, S.; Jiang, C. Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration. Biomaterials, 2011, 32(9), 2399-2406.
114. Wang, Z. H.; Wang, Z. Y.; Sun, C. S.; Wang, C. Y.; Jiang, T. Y.; Wang, S. L. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials, 2010, 31(5), 908-915.
115. Agyare, E. K.; Curran, G. L.; Ramakrishnan, M.; Yu, C. C.; Poduslo, J. F.; Kandimalla, K. K. Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy. Pharm. Res., 2008, 25(11), 2674-2684.
116. Yu, Y.; Pang, Z.; Lu, W.; Yin, Q.; Gao, H.; Jiang, X. Self-assembled polymersomes conjugated with lactoferrin as novel drug carrier for brain delivery. Pharm. Res., 2012, 29(1), 83-96.
117. Huile, G.; Shuaiqi, P.; Zhi, Y.; Shijie, C.; Chen, C.; Xinguo, J.; Shun, S.; Zhiqing, P.; Yu, H. A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. Biomaterials, 2011, 32(33), 8669-8675.
118. Kanwar, J. R.; Roy, K.; Kanwar, R. K. Chimeric aptamers in cancer cell-targeted drug delivery. Crit. Rev. Biochem. Mol. Biol., 2011, 46(6), 459-477.
119. Guo, J.; Gao, X.; Su, L.; Xia, H.; Gu, G.; Pang, Z.; Jiang, X.; Yao, L.; Chen, J.; Chen, H. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials, 2011, 32(31), 8010-8020.
120. Park, J.; Gao, W.; Whiston, R.; Strom, T. B.; Metcalfe, S.; Fahmy, T. M. Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. Mol. Pharm., 2011, 8(1), 143-152.
121. Marsh, J. N.; Hu, G.; Scott, M. J.; Zhang, H.; Goette, M. J.; Gaffney, P. J.; Caruthers, S. D.; Wickline, S. A.; Abendschein, D.; Lanza, G. M. A fibrin-specific thrombolytic nanomedicine approach to acute ischemic stroke. Nanomedicine (Lond), 2011, 6(4), 605-615.
122. Neely, A.; Perry, C.; Varisli, B.; Singh, A. K.; Arbneshi, T.; Senapati, D.; Kalluri, J. R.; Ray, P. C. Ultrasensitive and highly selective detection of Alzheimer's disease biomarker using twophoton Rayleigh scattering properties of gold nanoparticle. ACS Nano, 2009, 3(9), 2834-2840.
123. Van Kasteren, S. I.; Campbell, S. J.; Serres, S.; Anthony, D. C.; Sibson, N. R.; Davis, B. G. Glyconanoparticles allow presymptomatic in vivo imaging of brain disease. Proc. Natl. Acad. Sci. U S A, 2009, 106(1), 18-23.
124. Nel, A.; Xia, T.; Madler, L.; Li, N. Toxic potential of materials at the nanolevel. Science, 2006, 311(5761), 622-627.
125. Pisanic, T. R. 2nd; Blackwell, J. D.; Shubayev, V. I.; Finones, R. R.; Jin, S. Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. Biomaterials, 2007, 28(16), 2572-2581.
126. Kircher, M. F.; Mahmood, U.; King, R. S.; Weissleder, R.; Josephson, L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res., 2003, 63(23), 8122-8125.
127. Kim, Y. S.; Kim, J. S.; Cho, H. S.; Rha, D. S.; Kim, J. M.; Park, J. D.; Choi, B. S.; Lim, R.; Chang, H. K.; Chung, Y. H.; Kwon, I. H.; Jeong, J.; Han, B. S.; Yu, I. J. Twenty-eight-day oral toxicity, genotoxicity, and gender-related tissue distribution of silver nanoparticles in Sprague-Dawley rats. Inhal. Toxicol., 2008, 20(6), 575-583.
128. Shirahama H, Y. H. Biodegradable plastics and polymers. Elsevier: Amsterdam, 1994.
129. Kunwar, S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir. Suppl., 2003, 88, 105-111.
130. Brem, H.; Piantadosi, S.; Burger, P. C.; Walker, M.; Selker, R.; Vick, N. A.; Black, K.; Sisti, M.; Brem, S.; Mohr, G.; et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet, 1995, 345(8956), 1008-1012.
131. Santini, J. T. Jr.; Cima, M. J.; Langer, R. A controlled-release microchip. Nature, 1999, 397(6717), 335-338.
132. Baratchi, S.; Kanwar, R. K.; Kanwar, J. R. Survivin mutant protects differentiated dopaminergic SK-N-SH cells against oxidative stress. PLoS ONE, 2011, 6(1), e15865.
133. Baratchi, S.; Kanwar, R. K.; Kanwar, J. R. Novel survivin mutant protects differentiated SK-N-SH human neuroblastoma cells from activated T-cell neurotoxicity. J. Neuroimmunol., 2011, 233(1-2), 18-28.
134. Baratchi, S.; Kanwar, R. K.; Cheung, C. H.; Kanwar, J. R. Proliferative and protective effects of SurR9-C84A on differentiated neural cells. J Neuroimmunol, 2010, 227(1-2), 120-132.
135. Kanwar, J. R.; Kanwar, R. K.; Wang, D.; Krissansen, G. W. Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression. Immunol. Cell. Biol., 2000, 78(6), 641-645.
136. Kanwar, J. R.; Kanwar, R. K.; Krissansen, G. W. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain, 2004, 127(Pt 6), 1313-1331.
137. Wengel, J. Synthesis of 3'-C- and 4'-C-branched oligonucleotides and the development of locked nucleic acid (LNA). Acc. Chem. Res., 1999(32), 301-310.
138. Obika, S.; Nanbu, D.; Hari, Y.; Morio, K.-i.; In, Y.; Ishida, T.; Imanishi, T. Synthesis of 2'-O, 4'-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3, -endo sugar puckering. Tetrahedron Lett., 1997, 38(50), 8735-8738.
139. Langer, K.; Coester, C.; Weber, C.; Von Briesen, H.; Kreuter, J. Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid. Eur. J. Pharm. Biopharm., 2000, 49(3), 303-307.
140. Luchetti, A.; Milani, D.; Ruffini, F.; Galli, R.; Falini, A.; Quattrini, A.; Scotti, G.; Comi, G.; Martino, G.; Furlan, R.; Politi, L. S. Monoclonal antibodies conjugated with superparamagnetic iron oxide particles allow magnetic resonance imaging detection of lymphocytes in the mouse brain. Mol. Imag., 2012, 11(2), 114-125.